MedPath

Efficacy of monoclonal anti CD 20 antibodies in steroid and cyclosporin dependent nephrotic syndrome in children - ND

Conditions
ephrotic Syndrome
MedDRA version: 9.1Level: LLTClassification code 10029164Term: Nephrotic syndrome
Registration Number
EUCTR2008-004486-26-IT
Lead Sponsor
ISTITUTO GIANNINA GASLINI
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Age between 1-16 years 2-clinical picture of idiopathic nephrotic syndrome
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Positicity of autoantibodies and low levels of C3

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To define efficacy of antiCD20 antibodies to mantain remission in patients with nephrotic syndrome dependent to conventional drugs;Secondary Objective: To induce and mantain remission of proteinuria in children with nephrotic syndrome dependent to steroids and cyclosporin;Primary end point(s): To define efficacy of antiCD20 antibodies to mantain remission in patients with nephrotic syndrome dependent to conventional drugs
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath